Thrombocytopenia News and Research

RSS

Thrombocytopenia is a condition in which there is a lower-than-normal number of platelets in the blood. It may result in easy bruising and excessive bleeding from wounds or bleeding in mucous membranes and other tissues.

Millennium announces data on VELCADE in treatment of patients with amyloidosis

Millennium: The Takeda Oncology Company today announced data examining the use of VELCADE in the treatment of patients with relapsed or refractory light chain (AL) amyloidosis. Amyloidosis is a rare condition in which excessive proteins build up in organs or tissues, such as the heart, kidney or liver. These data were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Illinois, June 4-8, 2010.

5 Jun 2010

Amgen to present Phase 2 study data of AMG 479 in metastatic pancreatic cancer at 2010 ASCO

Amgen today announced results from a small, randomized, placebo-controlled Phase 2 study indicating that adding AMG 479 to gemcitabine improved overall survival at six months (primary endpoint) and progression-free survival in patients with metastatic pancreatic cancer. The study, which also included a separate arm of conatumumab plus gemcitabine, is being presented in a Poster Discussion at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting.

5 Jun 2010

Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

Onyx Pharmaceuticals, Inc. today announced updated interim results of the Phase 1b dose-escalation trial, known as the 006 study, evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed and/or refractory myeloma. These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

5 Jun 2010

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.

4 Jun 2010

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.

4 Jun 2010

Allos Therapeutics' FOLOTYN data to be presented at 46th ASCO and 15th EHA Congress

Allos Therapeutics, Inc. today announced that data on FOLOTYN® (pralatrexate injection) will be presented at two upcoming medical conferences: the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held June 4-8 in Chicago, Illinois, and at the 15th Congress of the European Hematology Association (EHA), which will be held June 10-13 in Barcelona, Spain.

2 Jun 2010

OnePath Gaucher Application available for patients with Type 1 Gaucher disease

Shire plc, the global specialty biopharmaceutical company, today announced the availability of the OnePath Gaucher Application. The first and only application developed specifically for patients in the U.S. with Type 1 Gaucher disease, it is free and ready for download at the iTunes Application store.

24 May 2010

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

Abraxis BioScience, Inc., a fully integrated biotechnology company, previously announced it will be presenting more than 30 studies, including new clinical data evaluating the use of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable suspension; paclitaxel protein albumin-bound particles for injectable suspension) for the treatment of pancreatic cancer at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Pfizer Oncology will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology meeting in Chicago from June 4-8.

21 May 2010

Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation

Results of two Phase II trials evaluating ALIMTA (pemetrexed for injection) in combination with a platinum chemotherapy and radiation for patients with locally advanced non-small cell lung cancer will be presented by Eli Lilly and Company at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago, Ill., on June 6, 2010.

21 May 2010

Phase II study results of Lilly Oncology's tasisulam for metastatic melanoma to be presented at 46th ASCO

Lilly released results today from a Phase II study evaluating Lilly Oncology's tasisulam, a novel anti-cancer agent, in patients with metastatic melanoma, the deadliest form of skin cancer. Study results will be presented during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. on June 6, 2010.

21 May 2010

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Takeda Pharmaceutical Company Limited and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced that Takeda has entered into a co-promotion agreement with Janssen Pharmaceutical K.K. for VELCADE® (bortezomib) for Injection, a treatment for patients with multiple myeloma.

10 May 2010

Allos Therapeutics reports net loss of $20.5 million for first-quarter 2010

Allos Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010.

6 May 2010

New data on Cimzia for Crohn’s Disease treatment to be demonstrated at DDW 2010

Studies and analyses of the Crohn’s Disease (CD) treatment Cimzia® (certolizumab pegol) demonstrating new data will be exhibited at Digestive Disease Week (DDW) 2010, taking place in New Orleans from May 1-5, 2010.

30 Apr 2010

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

The US Food and Drug Administration (FDA) has approved Zortress® (everolimus) oral tablets for the prevention of rejection of kidney transplants in adult patients at low-to-moderate immunologic risk. Zortress is to be given in combination with reduced doses of the calcineurin inhibitor (CNI) cyclosporine, as well as basiliximab and corticosteroids.

22 Apr 2010

ABRAXANE-bevacizumab combination therapy may exhibit potential in treatment of triple-negative breast cancers

Abraxis BioScience, Inc., a fully integrated biotechnology company, announced study results today that demonstrate a regimen of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) given in combination with bevacizumab (Avastin®) may have potential in the treatment of triple-negative breast cancers.

21 Apr 2010

Alexion Pharmaceuticals completes enrollment in Soliris clinical studies for aHUS

Alexion Pharmaceuticals, Inc. today announced that it has completed enrolling patients in all four previously announced prospective, open-label clinical studies investigating Soliris® (eculizumab) as a potential treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) being conducted in North America and multiple European countries.

21 Apr 2010

Updated survival data from Phase I/II trial of nab-paclitaxel, gemcitabine combination for pancreatic cancer

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced updated overall survival findings from a phase I/II study of nab®-paclitaxel (ABRAXANE® for Injectable Suspension) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) given in combination with gemcitabine, demonstrated increased survival of the first-line treatment of patients with advanced pancreatic cancer.

19 Apr 2010

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Genzyme Corporation today reported four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial showing an estimated 71 percent of alemtuzumab treated patients remain free of clinically-active disease as much as three years after most patients received their last course of the investigational compound. The data were presented at the American Academy of Neurology annual meeting.

15 Apr 2010

Rigel Pharmaceuticals, AstraZeneca license agreement: Waiting period under Antitrust Improvements Act expires

Rigel Pharmaceuticals, Inc. today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 relating to the license agreement between Rigel and AstraZeneca, the effectiveness of which was contingent on the expiration of the waiting period.

29 Mar 2010

Thrombocytopenia News and Research

Millennium announces data on VELCADE in treatment of patients with amyloidosis

Amgen to present Phase 2 study data of AMG 479 in metastatic pancreatic cancer at 2010 ASCO

Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Allos Therapeutics' FOLOTYN data to be presented at 46th ASCO and 15th EHA Congress

OnePath Gaucher Application available for patients with Type 1 Gaucher disease

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation

Phase II study results of Lilly Oncology's tasisulam for metastatic melanoma to be presented at 46th ASCO

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Allos Therapeutics reports net loss of $20.5 million for first-quarter 2010

New data on Cimzia for Crohn’s Disease treatment to be demonstrated at DDW 2010

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

ABRAXANE-bevacizumab combination therapy may exhibit potential in treatment of triple-negative breast cancers

Alexion Pharmaceuticals completes enrollment in Soliris clinical studies for aHUS

Updated survival data from Phase I/II trial of nab-paclitaxel, gemcitabine combination for pancreatic cancer

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Rigel Pharmaceuticals, AstraZeneca license agreement: Waiting period under Antitrust Improvements Act expires

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News